About Enhancer
| Enhancer ID: | E_03339 |
| Species: | Homo sapiens |
| Position : | chr18:48949564-48951076   |
| Year: | 2022 |
| Title: | HDAC5-mediated Smad7 silencing through MEF2A is critical for fibroblast activation and hypertrophic scar formation. |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | hepatocellular carcinoma |
| PMID: | 36263180 |
| MONDO: | MONDO:0007256 |
| Tissue: | liver |
| Tissue Ontology ID: | UBERON:0002107 |
| Cell Source: | Huh-7 |
| CVCL ID: | CVCL_0336 |
| Cell Type: | malignant cell |
| Cell Ontology ID: | CL:0001064 |
| Experiment Type: | Enhancer activity assay, TF binding assay; Enhancer activity assay; TF binding assay; In vivo functional validation |
| Low Throughput Method: | Luciferase Reporter Assay, ChIP-RT-qPCR; Luciferase reporter assay; ChIP-qPCR; ChIP; In vivo phenotyping; Reporter assay |
About Target Gene
| Target gene : | SMAD7 |
About TF
| TF name : | MEF2A |
About Regulatory State
| Regulatory State : | Active |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| MEF2A | CDO in myogenesis | reactome | 29 |
| MEF2A | ERK/MAPK targets | reactome | 17 |
| MEF2A | Signaling mediated by p38-alpha and p38-beta | pid | 35 |
| MEF2A | TGF_beta_Receptor | netpath | 220 |
| MEF2A | Hs_p38_MAPK_Signaling_Pathway_WP400_72084 | wikipathways | 28 |
Enhancer Associated Network
Overlapping Enhancers (hg38)
No overlapping enhancers found in hg38 at this locus.
Expression of Target Genes for the Enhancer